Clinical Trial

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Study acronym: WUKONG-32
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive non-small cell lung cancer. Condition or disease Intervention/treatment Phase Non-Small Cell Lung Cancer Drug: sunvozertinib Drug: anlotinib Phase 2
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-04.
Status change: Not Yet Recruiting → Recruiting 2024-09-17
Trial Details
NCT Number NCT06348927
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non-Small Cell Lung Cancer
Enrollment 52 participants
Start Date 2024-07-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19